Beckman Coulter Introduces The DxA 5000, A Revolutionary Automation Solution To Enable Laboratories Set a New Standard For Turnaround Time


  • The DxA 5000 provides the industry’s most comprehensive pre-analytical sample quality assessment and improves laboratory efficiency
  • The DxA 5000 is a key component of Beckman’s vision to bring workflow automation to laboratories of all sizes

June, 11 2019 – Beckman Coulter, the global leader in clinical diagnostics, announces today the launch of DxA 5000, a revolutionary automation solution designed to enable laboratories set a new standard for turnaround time.

Today’s healthcare environment requires laboratories to focus on improving turnaround times, quality of results, and operational efficiency. By leveraging a collection of patented innovations, the DxA 5000 total laboratory automation solution helps laboratories meet these challenges by driving faster turnaround times, providing a new level of comprehensive pre-analytical sample quality detection, and reducing manual processing steps to improve efficiency.

Reporting results faster to physicians can positively impact patient outcomes. In the laboratory, specimen centrifugation is typically the most time-consuming pre-analytical activity[1][2]. The DxA 5000 sets a new standard by utilizing a universal centrifugation protocol that reduces the pre-analytical processing time by up to 73% for connected analyzers across multiple disciplines[3].  Additionally, the DxA 5000 supports laboratories in delivering highly consistent turnaround time to their physicians. Leveraging first-of-its-kind dynamic system software, the DxA 5000 utilizes Intelligent Routing to bring automated patient-centric workflow to the laboratory. By understanding the tests requested, sample volume available and real-time analyzer capacity and status, the DxA 5000 continuously calculates the most expeditious route for every patient sample, both STAT and routine.

The DxA 5000 is a breakthrough solution in total laboratory automation, focused on enhancing the efforts of our laboratory partners to positively impact patient outcomes,” said John Blackwood, Beckman Coulter’s senior vice president of products and services. “By accelerating and reducing variability in turnaround time, laboratories can more efficiently provide physicians with the critical information they need to best manage patient care in an environment where every minute matters.”

Unmatched Quality Assessment and Improved Efficiency

Research shows errors that occur in the pre-analytical phase of testing may contribute up to 75% of erroneous test results, with 26% possibly having adverse effects on patient care [4]. Moreover, a vast majority of the factors causing erroneous results occurs outside the laboratory, including inadequate volume, mislabeled samples, and incorrect tube type[5][6][7][8]. The DxA 5000 is designed with a sharp focus on sample quality assessment, screening each sample at multiple points to help laboratories substantially reduce the risk of errors. In three seconds, the system detects patient tube parameters. The system is also designed to check for sample volume at three separate points: pre-centrifugation, post-centrifugation, and prior to sample storage to continually ensure sufficient volume is available for the tests ordered. Together, these quality assessments reduce the potential for release of erroneous results and help accelerate time to result by quickly alerting the laboratory when a new patient sample is needed.

The DxA 5000 is a key component of Beckman’s vision to bring workflow automation to laboratories of all sizes. This launch is the culmination of years of customer-inspired design and rigorous reliability testing and strengthens the company’s commitment to providing solutions that deliver results with fast, consistent turnaround time, better detection of pre-analytical errors, and more efficient workflows designed to fit the needs of any size laboratory. The DxA 5000 total laboratory automation solution has achieved European CE Mark and China Food and Drug Administration approval.

 About Beckman Coulter

Beckman Coulter is committed to advancing healthcare for every person by applying the power of science, technology, and the passion and creativity of our teams to enhance the diagnostic laboratory’s role in improving healthcare outcomes. Our diagnostic systems are used in complex biomedical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. Beckman Coulter offers a unique combination of people, processes, and solutions designed to elevate the performance of clinical laboratories and healthcare networks. We do this by accelerating care with a menu that matters, bringing the benefit of automation to all, delivering greater insights through clinical informatics and unlocking hidden value through performance partnership. An operating company of Danaher Corporation since 2011, Beckman Coulter is headquartered in Brea, California, and has more than 11,000 global associates working to make the world a healthier place.

*The DxA 5000 is pending 510(k) clearance by the U.S. FDA. Not yet available for in vitro diagnostic use in the U.S. For

Investigational Use Only. The performance characteristics of this product have not been established.

© 2019 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service

marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

[1] Estey CA, Felder RA. Clinical evaluation of serial blood processing at point-of-care. Clin Chem 1997;43:360-2

[2] Roberts T, Smith M, Roberts B. Observations in centrifugation: application to centrifuge development. Clin Chem 1999;45:1889-97

[3] Beckman Coulter Study, “Reducing the turnaround time of the pre-analytical phase by application of a rapid centrifugation profile.” S. Frankenberger, et al.

[4] Green. Sol. F., Clinical Biochemistry 46 (2013), 1175–1179

[5] J Clin Diagn Res, Nov; 7(11): 2491–2493. 2013

[6] LabMedicine, 41, 89-92. (2010).

[7] Clinical Chemistry 53:7, 1338–1342 (2007).

[8] DOI 10.1515/cclm-2013-0597. Clin Chem Lab Med 2013; aop.

This Press Release has been sponsored by Beckman Coulter

Digital Health Buzz!

Digital Health Buzz!

Digital Health Buzz! aims to be the destination of choice when it comes to what’s happening in the digital health world. We are not about news and views, but informative articles and thoughts to apply in your business.

Hey there!

Sign in

Forgot password?

Don't have an account? Register


    Processing files…